Akeso's IO Bispecifics Drive 51% Revenue Surge, Expanding Oncology Portfolio
Event summary
- Akeso reported RMB3,033.1 million (approximately $420 million USD) in commercial sales revenue for 2025, a 51.48% year-over-year increase.
- All approved Akeso products and indications are now included in China's National Reimbursement Drug List (NRDL).
- Key clinical trial results, including head-to-head wins for Ivonescimab against pembrolizumab and superiority over tislelizumab, have bolstered commercial adoption.
- Akeso is expanding its oncology portfolio beyond bispecifics into trispecifics and ADCs, with AK150 (trispecific) currently in clinical development.
The big picture
Akeso's rapid revenue growth and clinical successes underscore the increasing demand for novel immuno-oncology therapies in China and globally. The company's strategic pivot towards combining bispecifics with ADCs and trispecifics represents a bet on next-generation cancer treatments, aiming to overcome limitations of existing therapies. Akeso's aggressive expansion into immune-related diseases further diversifies its pipeline and reduces reliance on oncology.
What we're watching
- Regulatory Approval
- The approval timeline for the sNDA for Ivonescimab in China will be a key indicator of the drug's long-term commercial potential.
- ADC Integration
- The success of Phase II trials combining Akeso's bispecific ADCs with cadonilimab and ivonescimab will determine the viability of its 'IO 2.0 + ADC 2.0' strategy.
- Global Expansion
- The pace of global clinical expansion, particularly in the US, will be crucial for Akeso to realize its full market potential.
Related topics